Aranscia Acquires Spesana to Advance Precision Oncology

What You Should Know: 

– Aranscia, a global provider of award-winning clinical workflow and diagnostic technology solutions announced its strategic acquisition of Spesana and its best-in-class suite of patient navigation, clinical collaboration, and oncology clinical decision support utilities. 

– As part of the acquisition, Spesana’s Founder and CEO, Carla Balch, a renowned pioneer in healthcare and oncology information systems, will assume the role of Executive Director across all Aranscia software solutions. This includes overseeing Spesana’s continued commercial and technical expansion.

Spesana: Streamlining Precision Medicine and Oncology Care

Founded in 2019, Spesana has developed a healthcare platform designed to increase the velocity, efficiency, and utility of innovative precision medicine programs. The company’s solutions are currently utilized across more than 140 clinical sites.

Spesana’s platform offers a comprehensive suite of tools, including patient navigation, prior authorization assistance, clinical trial collaboration features, and diagnostic workflow solutions. Its blue-chip customer base comprises leading payers, multi-site provider and oncology organizations, and diagnostic laboratories. Clients using Spesana’s intelligent platform utilities have reported significant benefits, including a notable 60% improvement in the appropriate use of precision medicine diagnostics by eliminating clinical overhead and process ambiguity.

Strategic Integration into Aranscia’s Precision Care Portfolio

The acquisition will see Spesana join Aranscia’s growing portfolio of companies, all of which share a synergistic mission focused on solving tactical gaps in clinical workflows and democratizing access to the advancements of precision care. This esteemed portfolio already includes:

• 2bPrecise: An award-winning platform known for its lab-agnostic, EMR-integrated solutions that deliver unparalleled speed-to-value in implementing precision care.
• YouScript: A widely recognized leader providing actionable, real-time personalized medication risk management and pharmacogenomics (PGx) insights.
• AccessDx Laboratory: A CLIA-certified, CAP-accredited, and NYCQ molecular diagnostic laboratory with specialist expertise in PGx and other personalized diagnostics.

Carla Balch to Lead Software Solutions Expansion

The leadership of Carla Balch in her new role as Executive Director is a key component of the acquisition. Ms. Balch brings a wealth of experience and a pioneering track record in the healthcare technology sector, particularly in oncology. She was previously the President and CEO of Altos Solutions, which developed OncoEMR, the first web-based oncology electronic medical records company, later acquired by Flatiron Health (now part of Roche). Prior to founding Spesana, Ms. Balch also served as President of Nantcare, an oncology technology and clinical trials company, and as CEO of Inteliquet, an innovative clinical trial matching solution acquired by IQVIA. She currently serves on the Healthcare Counsel of the Federal Reserve Bank of St. Louis.